Sugi Predict

Sugi Predict / Targets / CCNE2

CCNE2

G1/S-specific cyclin-E2 · O96020 · CCNE2 on Sugi Atlas →

68,808 patent compounds predicted against CCNE2, 45,971 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12466 SCHEMBL12466 0.58 16/20
SCHEMBL12292 SCHEMBL12292 0.59 14/20
SCHEMBL179490 SCHEMBL179490 0.52 12/20
SCHEMBL412212 SCHEMBL412212 0.66 11/20
SCHEMBL409805 SCHEMBL409805 0.64 11/20
SCHEMBL408691 SCHEMBL408691 0.61 11/20
SCHEMBL411266 SCHEMBL411266 0.59 11/20
Clonazepam Clonazepam (SCHEMBL357481) 0.47 11/20
SCHEMBL160631 SCHEMBL160631 0.40 11/20
SCHEMBL407802 SCHEMBL407802 0.71 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL411390) 0.70 10/20
SCHEMBL411857 SCHEMBL411857 0.70 10/20
SCHEMBL411037 SCHEMBL411037 0.69 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL410806) 0.68 10/20
SCHEMBL410132 SCHEMBL410132 0.68 10/20
SCHEMBL411691 SCHEMBL411691 0.68 10/20
SCHEMBL413176 SCHEMBL413176 0.67 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL411919) 0.67 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL412197) 0.67 10/20
Clonazepam Clonazepam (SCHEMBL38899) 0.59 10/20

Clinical trials — most relevant to CCNE2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor PHASE1/PHASE2RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum PHASE2COMPLETED
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) PHASE2UNKNOWN
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors PHASE1/PHASE2WITHDRAWN
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PHASE1SUSPENDED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) PHASE1COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy nanCOMPLETED
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. nanRECRUITING
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNE2 binder may also engage these)

ProteinNameSimilarity
Q9Z238 — 1.000 Q9Z238 →
Q5E9K7 — 0.998 Q5E9K7 →
P50756 — 0.996 P50756 →
Q91780 — 0.996 Q91780 →
Q61457 — 0.993 Q61457 →
CCNE1 G1/S-specific cyclin-E1 0.993 landscape →
P49707 — 0.992 P49707 →
P39949 — 0.991 P39949 →
O42575 — 0.991 O42575 →
P47794 — 0.990 P47794 →
O15995 — 0.985 O15995 →
P55169 — 0.983 P55169 →
Q16589 — 0.983 Q16589 →
P25322 — 0.983 P25322 →
Q32NM1 — 0.981 Q32NM1 →
Q90459 — 0.981 Q90459 →
Q64HP0 — 0.981 Q64HP0 →
P39948 — 0.980 P39948 →
Q8WNW2 — 0.980 Q8WNW2 →
Q0P5D3 — 0.980 Q0P5D3 →
CCND1 G1/S-specific cyclin-D1 0.980 landscape →
Q9SA32 — 0.979 Q9SA32 →
Q52QT8 — 0.979 Q52QT8 →
Q2KI22 — 0.978 Q2KI22 →
CCND2 G1/S-specific cyclin-D2 0.978 landscape →
Q04827 — 0.978 Q04827 →
P49706 — 0.978 P49706 →
P51945 — 0.976 P51945 →
Q9D995 — 0.976 Q9D995 →
P30280 — 0.976 P30280 →